CCM
PRTK

Cadence Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Cadence Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-78,372
Closed -$799K – 722
2018
Q2 		$799K Buy
78,372
+8,509
+12% +$96.3K 0.05% 429
2018
Q1 		$908K Buy
69,863
+20,535
+42% +$306K 0.06% 409
2017
Q4 		$883K Buy
49,328
+24,806
+101% +$518K 0.06% 403
2017
Q3 		$616K Buy
24,522
+1,192
+5% +$27.7K 0.04% 462
2017
Q2 		$562K Buy
+23,330
New +$516K 0.04% 494

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Cadence Capital Management's PRTK Position: Q3 2018 in Review

Cadence Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2018, closing a stake of 78,372 shares — an estimated $799K sold.

Cadence Capital Management first reported a position in PRTK in Q2 2017 and held it in 5 quarters. The position peaked at $908K in Q1 2018. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2018.

  • Cadence Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Cadence Capital Management sold 78,372 Paratek Pharmaceuticals, Inc. shares in Q3 2018, an estimated $799K.
  • Cadence Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 5 quarters.
  • Cadence Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $908K in Q1 2018.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2018.

Based on Cadence Capital Management's 13F filing for Q3 2018, filed 2 Nov 2018.